ArticleThe oncologist2013
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.
Article in The oncologist, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review.Clinical lymphoma, myeloma & leukemia · 2023Pooled it
- Financial Hardships Experienced by Cancer Survivors: A Systematic Review.Journal of the National Cancer Institute · 2017Pooled it
- Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis.PharmacoEconomics - open · 2026Article
- Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study.International journal of medical sciences · 2025Article
- Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.JCO oncology practice · 2024Article
- Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.Journal of managed care & specialty pharmacy · 2023Article
- Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.The patient · 2023Article
- Article
- Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US.Blood cancer journal · 2021Article
- Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2021Article
- Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma.Clinical lymphoma, myeloma & leukemia · 2020Article
- Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Journal of managed care & specialty pharmacy · 2020Article
- Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant of hematopoietic progenitor cells.Bone marrow transplantation · 2019Article
- A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.Journal of managed care & specialty pharmacy · 2019Article
- Review
- Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.Bone marrow transplantation · 2018Article
- Balancing patient value and payer cost in hematologic malignancies: can it be done?Expert review of pharmacoeconomics & outcomes research · 2018Article
- Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.American health & drug benefits · 2018Article
- Uncovering Longitudinal Health Care Behaviors for Millions of Medicaid Enrollees: A Multistate Comparison of Pediatric Asthma Utilization.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background. Treatment of multiple myeloma has dramatically improved with the introduction of bortezomib (BOR), thalidomide (THAL), and lenalidomide (LEN). Studies assessing health care costs, particularly economic burden on patients, are limited. We conducted a claims-based, retrospective analysis of total health care costs as well as patient burden (patient out-of-pocket costs and number of ambulatory/hospital visits) associated with BOR/THAL/LEN treatment versus other therapies (OTHER). METHODS. Treatment episodes starting between January 1, 2005 and September 30, 2010 were identified from the claims database of a large U.S. health plan. Health care costs and utilization were measured during 1 year after initiation and analyzed per treatment episode. Multivariate analyses were used to adjust for patient characteristics, comorbidities, and line of treatment.
resultsA total of 4,836 treatment episodes were identified. Mean adjusted total costs were similar between BOR ($112,889) and OTHER ($111,820), but higher with THAL ($129,412) and LEN ($158,428). Mean adjusted patient out-of-pocket costs were also similar for BOR ($3,846) and OTHER ($3,900) but remained higher with THAL ($4,666) and LEN ($4,483). Mean adjusted rates of ambulatory visits were similar across therapies (BOR: 69.67; THAL: 66.31; LEN: 65.60; OTHER: 69.42).
conclusionsAdjusted analyses of real-world claims data show that total health care costs, as well as patient out-of-pocket costs, are higher with THAL/LEN treatment episodes than with BOR/OTHER therapies. Additionally, similar rates of ambulatory visits suggest that any perceived advantage in patient convenience of the orally administered drugs THAL/LEN is not supported by these data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.